Final Report of a Phase I Trial of Lipovaxin-MM, a Novel Dendritic Cell-Targeted Liposomal Vaccine for Malignant Melanoma. — ASN Events
  1. Schedule
  2. Posters1
  3. Final Report of a Phase I Trial of Lipovaxin-MM, a Novel Dendritic Cell-Targeted Liposomal Vaccine for Malignant Melanoma.

Final Report of a Phase I Trial of Lipovaxin-MM, a Novel Dendritic Cell-Targeted Liposomal Vaccine for Malignant Melanoma. (#180)

M N Abbas 1 , P Rolan 2 , J D Price 3 , K M Gosling 4 , I I C Atmosukarto 3 , C R Parish 4 , M P Brown 1
  1. Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia
  2. School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
  3. Lipotek Pty Ltd, Acton, Australian Capital Territory, Australia
  4. Department of Immunology, The Australian National University, Canberra, Australian Capital Territory, Australia
Publish consent withheld
#COSA2015